ASN: Empagliflozin Cuts Risk for Progression in CKD
Risk for progression of kidney disease or death from cardiovascular causes reduced with empagliflozin versus placebo
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.